Search Results

Biotechnology company Inventprise Inc.n announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine in young adults.

Biotechnology company Inventprise announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine has begun in Halifax, Canada.

Inventprise, a biotechnology company specializing in novel, affordable and impactful vaccines, announced the inauguration of its new manufacturing facility for high-capacity supply of a 25-valent Pneumococcal Conjugate Vaccine for low- and middle-income countries.

Inventprise, a biotechnology company specializing in novel, affordable and highly impactful vaccines, announced that the Bill & Melinda Gates Foundation, a global non-profit organization, has made a program-related investment in the company’s continued development of IVT-25, an investigational pneumococcal conjugate vaccine designed to prevent pneumococcal bacterial infections.

The Bill & Melinda Gates Foundation is taking up the cause for pneumococcal infection with a $90 million investment in Seattle area’s Inventprise.

Follow along as BioSpace tracks job cuts and restructuring initiatives.

While there had been hope layoffs would slow down in 2025, they continued at a fast pace, affecting even more people than in 2024, based on BioSpace tallies.

While layoffs slowed in the second half of 2024, biopharmas including Bayer, Bristol Myers Squibb and Johnson & Johnson cut hundreds or even thousands of employees over the course of the year.